Search

Preprint: Gram-positive bacteria evade phage predation through endolysin-mediated L-form conversion. Read author Martin Loessner’s Twitter thread on this report!

Opinion: Diversity in the soil virosphere: to infinity and beyond? Read author Simon Roux’s Twitter thread on this report!

Paper: Phage-mimicking nanoagents for rapid depolymerase specificity screening against multidrug resistant bacteria.

News article: Rediscovering phages: ‘We finally have the tools to harness them’.

Armata Pharmaceuticals announces first patient dosed in phase 1b/2a 'diSArm' study of AP-SA02 in adults with bacteremia due to Staphylococcus aureus.

Paper: A truncated anti-CRISPR protein prevents spacer acquisition but not interference

Paper: Computational tools for the analysis of uncultivated phage genomes

Paper: The gut environment regulates bacterial gene expression which modulates susceptibility to bacteriophage infection

Paper: An anti-MRSA phage from raw fish rinse: stability evaluation and production optimization.

Register here to attend the upcoming ESGNTA online course on ‘personalised phage therapy: basic principles of monitoring and treatment’. The online course will run from 7 - 10 June, 2022 with a great line-up of experts in the field.

Intralytix has been granted FDA clearance for an investigational new drug application for phase 1/2a clinical trials for vancomycin resistant Enterococci (VRE)-targeting phage.

Paper: Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. Also read this press release about the paper!

Paper: Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy. Also see this news article about the paper!

Pre-print: An expanding arsenal of immune systems that protect bacteria from phages.

Paper: In vitro and in vivo assessments of two newly isolated bacteriophages against an ST13 urinary tract infection Klebsiella pneumoniae.

New NIAID request for applications: Partnerships for the Development of Novel Therapeutics To Combat Select Antibiotic Resistant Bacteria and Fungi (R01, Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA

Paper: Cleavage of viral DNA by restriction endonucleases stimulates the type II CRISPR-Cas immune response. Also check out this Spotlight on the paper.

Paper: An Optimal Lysis Time Maximizes Bacteriophage Fitness in Quasi-Continuous Culture

Paper: Organizing the Global Diversity of Microviruses

Preprint: Cyclic nucleotide-induced superhelical structure activates a bacterial TIR immune effector